Contraception Clinical Trial
Official title:
Structured Contraceptive Counseling--A Randomized Controlled Trial
In the United States, highly effective methods of birth control are often not used.
Healthcare providers use birth control counseling and patient education as ways to increase
the usage of birth control. However, little evidence exists to show that patient education
and birth control counseling changes birth control use.
We want to evaluate the effectiveness of using a uniform set of birth control information to
provide birth control education to women having an early pregnancy termination. The
counselors will allow the clients to both read as well as hear the information. We propose
to evaluate whether this counseling will lead to 1) more women choosing highly effective
nonpermanent birth control methods and 2) more women continuing to use these methods for a
longer time.
Women in the study will complete a questionaire about their health. Half of them will have
the structured counseling and half will have the routine counseling currently offered to
women as a part of their routine care. We will contact all study participants with a
telephone call three months and six months later to have a 10 minute conversation about what
birth control they are using.
The proposed study will be a randomized controlled trial to evaluate the primary study
hypothesis that structured counseling immediately before a first trimester vacuum aspiration
procedure will result in more women choosing a highly effective contraceptive method
compared to women receiving routine care.
The study population consists of pregnant women seeking a first trimester suction procedure
in a single Medicaid-based practice in New York City. We need 125 participants in both the
control group and the intervention group for a total of 250 participants. The inclusion
criteria for enrollment in the study are (1) age greater than or equal to 18 years,(2)
seeking contraception, (3) Spanish or English speaking, (4) access to a telephone, and (5)
willing to participate in the study. We recognize that patients may be anxious about their
scheduled procedure. Information about the procedure will be available to all patients in
our clinic to inform and help alleviate anxiety.
After being consented, all participants will complete the baseline questionnaire.
Participants will then be randomized in a 1:1 ratio.
Those randomized to the control group will proceed to routine care. Routine care consists of
contraceptive counseling by the clinician performing the vacuum procedure. The clinician
will evaluate the medical eligibility of each participant for FDA-approved contraceptive
methods as part of routine care. Every clinician in the practice is a faculty member,
fellow, or resident physician training under faculty supervision.
Those randomized to the intervention group will engage in structured counseling with the
research coordinator, and then proceed to routine care. The structured counseling will take
place while the participant would normally be waiting for care. We will pay attention to
ensure that study participation does not prolong the clinic visit.
Structured counseling consists of a bilingual research coordinator going through the 2005
Decision Making Tool (D.M.T.) for family planning clients and providers developed by the
World Health Organization(W.H.O.). Samples of each FDA-approved method will be present
during the structured counseling session for participants to directly see and touch as
desired. The link to this freely available counseling tool in English and Spanish is
www.who.int/reproductivehealth/publications/dmt/index.html.
For our study, we modified the original version to include only FDA-approved contraceptive
methods available in the United States suitable for a post-abortion population. Information
about methods not available in the United States(NETEN injections, monthly injections and
norplant) was removed. Information about new FDA-approved methods available in the United
States (contraceptive patch, contraceptive ring, levonorgestrel IUS, and etonogestrel
implant),but not previously included, was added. Information about methods not appropriate
for post abortion patients (lactational amenorrhea and fertility awareness) was removed. We
performed all modifications with the full support and cooperation of Sarah Johnson,
technical officer in the Department of Reproductive Health and Research at the World Health
Organization. We have attached our modified version with this application.
All FDA-approved methods will be available to participants on the day of their scheduled
procedure for immediate initiation. Participants choosing an intrauterine device or implant
will be able to have them placed that day.
Participants choosing depot medroxyprogesterone acetate will be able to have the injection
that day. Participants choosing the pill, ring, or patch will receive a one month supply and
continuing prescription that day. All participants will receive condoms and information
about emergency contraception.
At the end of the visit, we will perform a brief secondary questionnaire. We will ask
participants to indicate their chosen FDA-approved method and identify if the method was
initiated that day.
Follow-up will take place at three months and six months with phone calls to obtain data
from participants about the contraceptive method adopted and the contraceptive method use
since enrollment.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |